You are in and would like to read our site in

Investigator-Initiated Studies

The aim of the UCB Investigator-Initiated Studies (IIS) program is to support unsolicited, and independently initiated and conducted, studies that have the potential to enhance medical and scientific knowledge.

Therapeutic Areas of Interest
Divider text here

UCB is primarily focused on the following areas of therapeutic expertise (alphabetically listed):

Ankylosing Spondylitis Parkinson's Disease
Axial Spondyloarthritis Psoriatic Arthritis
Crohn's Disease Restless Legs Syndrome
Epilepsy Rheumatoid Arthritis
Low Bone Mass Disorder Systemic Lupus Erythematosus

UCB will also consider innovative ideas that enhance patient care and advance scientific knowledge.

UCB support may be provided in the form of funding and/or investigational drugs (product or compound manufactured/owned by UCB).

Timelines
Divider text here

Month in Review Review Type Submission Due Date
January Concept 27 December 2016
February Concept 30 January 2017
March Concept 15 February 2017
April Concept 20 March 2017
May Concept 20 April 2017 (Immunology Only)
June Concept 29 May 2017 (Immunology Only)
July Concept 21 June 2017
August Concept 24 July 2017
September Concept 21 August 2017 (Immunology Only)
October Concept 20 September 2017
November Concept 25 October 2017
December Concept 20 November 2017 (Immunology Only)
Submitting a Concept
Divider text here

UCB is using the eRequest on-line submission portal to manage all Investigator-Initiated Study requests worldwide. To submit a concept, please click here: erequest.ucb.com

If a concept is recommended for a full proposal submission, an IIS Team member will contact the applicant with instructions.

eRequest is available for IIS submissions worldwide.

Contact
Divider text here

You can contact your local UCB Medical Science Liaison or UCB Medical Affairs office in your country.

All IIS process queries should be sent to IISmailbox@ucb.com.